SUBSCRIBE
SUBSCRIBE
Heather McKenzie

Heather McKenzie

Senior Editor

Heather McKenzie is a professional journalist with more than five years experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 200 features and breaking news articles with a particular focus in neuroscience and gene therapy. She has also traveled internationally to cover global biotech hubs such as Israel. In previous roles, she has covered current affairs, sports, education and politics. She previously spent eight years as a senior content producer for executive-level business conferences in the pharma/biotech, legal, energy and business strategy sectors. In her free time, Heather enjoys creative writing, spending time with family and playing with her energetic Russian Blue cat Roofus. She hails from Toronto and has also lived in Chicago and Chesapeake, Virginia. You can reach her at heather.mckenzie@biospace.com.

BioForest
Biopharma Executive Perspectives on 2021
The lessons learned from the global pandemic are expected to translate to existing and emerging therapeutic areas - particularly oncology; more efficient regulatory-industry relationships; mRNA is a word we will continue to hear a lot about; and home health care is here to stay.
January 11, 2021
 · 
14 min read
 · 
Heather McKenzie
Business
Fujifilm Diosynth Makes Another Big Splash In the U.S. Market
Morrisville, North Carolina, has reason to hope that it may be the beneficiary of Fujifilm’s next major investment, a $2 Billion USD large-scale cell culture manufacturing site which the company said will be located near one of its current facilities.
January 7, 2021
 · 
2 min read
 · 
Heather McKenzie
Business
Autolus Aligns Pipeline Around Promising CAR T Cell Therapy Candidate
The recalibration will also have workforce implications, including an overall workforce reduction of approximately 20% during Q1, 2021.
January 6, 2021
 · 
2 min read
 · 
Heather McKenzie
Drug Development
Six Life Sciences Successes and Failures To Kick Off 2021
2021 is off to a hopeful start for some companies, executives and scientists, while others are forced to fold programs and recalibrate.
January 5, 2021
 · 
6 min read
 · 
Heather McKenzie
Biotech Bay
New and Emerging Drug Classes That Will Outlast the Pandemic
From synthetic polymer-based anti-infectives to antiviral conjugates and DNA vaccines, the past year has given new and emerging drug classes an opportunity to shine.
December 31, 2020
 · 
8 min read
 · 
Heather McKenzie
Drug Development
Therapeutics for ‘COVID-19 Long-Haulers’ Exploding onto the Scene as 2020 Ends
BioSpace spoke with just a couple of companies endeavoring to make 2021 a happier new year for survivors now suffering from the life-altering after-effects of COVID-19.
December 23, 2020
 · 
5 min read
 · 
Heather McKenzie
Biotech Beach
Neomorph to Leverage $109 Million Series A Funds Against Undruggable Targets
It is already a very Merry Christmas for brand new San Diego-based biotech Neomorph, Inc., which found $109 million under the tree in a Series A financing to advance its proprietary protein degradation platform and programs.
December 23, 2020
 · 
2 min read
 · 
Heather McKenzie
JHVEPhoto/Shutterstock
Policy
Sackler Family Side-Step Personal Responsibility for Opioid Crisis
In their first appearance in years, the notorious Sackler family, who previously headed OxyContin maker Purdue Pharma, apologized to victims of the opioid crisis but stopped short of admitting personal responsibility during a nearly four-hour grilling from the U.S. House Oversight and Reform Committee.
December 18, 2020
 · 
2 min read
 · 
Heather McKenzie
FDA approved Ascendis Pharma’s Skytrofa.
FDA
FDA Approvals: Therapies for Lupus, MS, Cancer and a Genomic Alteration in Pigs
The U.S. Food and Drug Administration (FDA) had several approvals this week. Read on to see what the regulatory agency gave the go-ahead to.
December 17, 2020
 · 
6 min read
 · 
Heather McKenzie
Drug Development
Four Potential Biotech Market Movers to Watch Going into 2021
As we eagerly look ahead to 2021, BioSpace spoke to four biotechs hoping to seize this opportunity in the first wave of COVID-19 vaccines and therapies – or make an impact in the second.
December 17, 2020
 · 
9 min read
 · 
Heather McKenzie
Business
A Bright Day for Two Companies as New CEOs Announced
On Wednesday, Sage Therapeutics and Samsung Biologics announced that they had found just that in their new chief executive officers.
December 17, 2020
 · 
3 min read
 · 
Heather McKenzie
Courtesy Taljat David/Getty Images
Drug Development
Novartis’ KESTREL Study Reaffirms Positive Results of Beovu in DME
On Tuesday, Novartis announced the first interpretable results from its Phase III KESTREL study of humanized single-chain antibody fragment (scFv) Beovu, demonstrating significant improvement in central subfield thickness in Diabetic Macular Edema.
December 15, 2020
 · 
2 min read
 · 
Heather McKenzie
Business
Difficult Decisions, Strategic Streamlining Lead to Workforce Reductions
Mergers and acquisitions are a well-known fact in the life sciences industry, and anyone working within the sector knows to expect them at any time.
December 15, 2020
 · 
4 min read
 · 
Heather McKenzie
Courtesy of uniQure
Drug Development
uniQure Phase III HOPE-B Trial Signals Hope for Hemophilia B Patients Everywhere
In a shining moment that signaled hope for hemophilia B patients, uniQure presented data on Tuesday showing that its gene therapy treatment, etranacogene dezaparvovec (AMT-061), substantially increased production of the blood-clotting protein factor IX in nearly all pivotal Phase III HOPE-B trial participants.
December 11, 2020
 · 
3 min read
 · 
Heather McKenzie
Bio NC
Innovative Companies Diving into The Neuro Market Ahead of 2021
With the expected Emergency Use Authorization (EUA) of Pfizer-BioNTech and Moderna’s COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Could it come from the field of neuroscience?
December 9, 2020
 · 
4 min read
 · 
Heather McKenzie
Load More